SUMMARY: We evaluated the relation between serum FGF23 and bone mineral density (BMD) in a community-based cohort of elderly men. There was a weak correlation between FGF23 and BMD, which was primarily dependent on body weight. INTRODUCTION: FGF23 is a hormonal factor produced in bone and regulates serum levels of phosphate (Pi) and vitamin D. FGF23 over-expression is associated with skeletal abnormalities, including rickets/osteomalacia. The relation between FGF23 and Bone Mineral Density (BMD) in the community remains unexplored. METHODS: We employed a large, population-based cohort of 3014 Swedish men aged 69-80 years, without known renal disease. BMD was measured with dual X-ray absorptiometry (DXA) in the hip and lumbar spine. Serum intact FGF23 was analyzed with a two-site monoclonal ELISA. RESULTS: There was a weak but significant correlation between FGF23 and BMD in femoral neck (r = 0.04, p < 0.05), femoral trochanter (r = 0.05, p = 0.004), total hip (r = 0.06, p = 0.0015) and lumbar spine (r = 0.07, p = 0.0004). The correlations remained significant when adjusting for biochemical covariates (Pi, calcium, PTH, 25(OH)D and renal function). However, the association became insignificant in all regions when adjusting for established confounding variables including age, height, weight and smoking. Further analysis confirmed a significant correlation between FGF23 and body weight (r = 0.13, p < 0.0001). CONCLUSIONS: The weak correlation between FGF23 and BMD in elderly male subjects is mainly due to an association between FGF23 and body weight. Therefore, FGF23 may not play a significant role in the hormonal regulation of BMD.
SUMMARY: We evaluated the relation between serum FGF23 and bone mineral density (BMD) in a community-based cohort of elderly men. There was a weak correlation between FGF23 and BMD, which was primarily dependent on body weight. INTRODUCTION:FGF23 is a hormonal factor produced in bone and regulates serum levels of phosphate (Pi) and vitamin D. FGF23 over-expression is associated with skeletal abnormalities, including rickets/osteomalacia. The relation between FGF23 and Bone Mineral Density (BMD) in the community remains unexplored. METHODS: We employed a large, population-based cohort of 3014 Swedish men aged 69-80 years, without known renal disease. BMD was measured with dual X-ray absorptiometry (DXA) in the hip and lumbar spine. Serum intact FGF23 was analyzed with a two-site monoclonal ELISA. RESULTS: There was a weak but significant correlation between FGF23 and BMD in femoral neck (r = 0.04, p < 0.05), femoral trochanter (r = 0.05, p = 0.004), total hip (r = 0.06, p = 0.0015) and lumbar spine (r = 0.07, p = 0.0004). The correlations remained significant when adjusting for biochemical covariates (Pi, calcium, PTH, 25(OH)D and renal function). However, the association became insignificant in all regions when adjusting for established confounding variables including age, height, weight and smoking. Further analysis confirmed a significant correlation between FGF23 and body weight (r = 0.13, p < 0.0001). CONCLUSIONS: The weak correlation between FGF23 and BMD in elderly male subjects is mainly due to an association between FGF23 and body weight. Therefore, FGF23 may not play a significant role in the hormonal regulation of BMD.
Authors: M Kuro-o; Y Matsumura; H Aizawa; H Kawaguchi; T Suga; T Utsugi; Y Ohyama; M Kurabayashi; T Kaname; E Kume; H Iwasaki; A Iida; T Shiraki-Iida; S Nishikawa; R Nagai; Y I Nabeshima Journal: Nature Date: 1997-11-06 Impact factor: 49.962
Authors: Tobias Larsson; Xijie Yu; Siobhan I Davis; Mohamad S Draman; Sean D Mooney; Michael J Cullen; Kenneth E White Journal: J Clin Endocrinol Metab Date: 2005-02-01 Impact factor: 5.958
Authors: Dan Mellström; Olof Johnell; Osten Ljunggren; Anna-Lena Eriksson; Mattias Lorentzon; Hans Mallmin; Anna Holmberg; Inga Redlund-Johnell; Eric Orwoll; Claes Ohlsson Journal: J Bone Miner Res Date: 2006-04-05 Impact factor: 6.741
Authors: Richard Marsell; Elin Grundberg; Tijana Krajisnik; Hans Mallmin; Magnus Karlsson; Dan Mellström; Eric Orwoll; Claes Ohlsson; Kenneth B Jonsson; Osten Ljunggren; Tobias E Larsson Journal: Eur J Endocrinol Date: 2008-01 Impact factor: 6.664
Authors: Jerry Meng; Claes Ohlsson; Gail A Laughlin; Michel Chonchol; Christina L Wassel; Osten Ljunggren; Magnus K Karlsson; Dan Mellstrom; Eric S Orwoll; Elizabeth Barrett-Connor; Joachim H Ix Journal: Kidney Int Date: 2010-06-09 Impact factor: 10.612
Authors: Carmen Streicher; Ute Zeitz; Olena Andrukhova; Anne Rupprecht; Elena Pohl; Tobias E Larsson; Wilhelm Windisch; Beate Lanske; Reinhold G Erben Journal: Endocrinology Date: 2012-01-31 Impact factor: 4.736
Authors: Erik A Imel; Ziyue Liu; Amie K McQueen; Dena Acton; Anthony Acton; Leah R Padgett; Munro Peacock; Michael J Econs Journal: Bone Date: 2016-03-08 Impact factor: 4.398
Authors: Nisha Bansal; Ronit Katz; Ian H de Boer; Bryan Kestenbaum; David S Siscovick; Andrew N Hoofnagle; Russell Tracy; Gail A Laughlin; Michael H Criqui; Mathew J Budoff; Dong Li; Joachim H Ix Journal: J Clin Endocrinol Metab Date: 2013-10-03 Impact factor: 5.958
Authors: Anna Jovanovich; Petra Bùzková; Michel Chonchol; John Robbins; Howard A Fink; Ian H de Boer; Bryan Kestenbaum; Ronit Katz; Laura Carbone; Jennifer Lee; Gail A Laughlin; Kenneth J Mukamal; Linda F Fried; Michael G Shlipak; Joachim H Ix Journal: J Clin Endocrinol Metab Date: 2013-06-14 Impact factor: 5.958